Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
Mayo Clinic
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
M.D. Anderson Cancer Center
Intima Bioscience, Inc.
M.D. Anderson Cancer Center
Essen Biotech
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
TCRCure Biopharma Ltd.
University of California, Irvine
Memorial Sloan Kettering Cancer Center
Hadassah Medical Organization
Valo Therapeutics Oy
TCR2 Therapeutics
TCR2 Therapeutics
Qingdao Sino-Cell Biomedicine Co., Ltd.
Memorial Sloan Kettering Cancer Center
University of Pittsburgh
ImmunityBio, Inc.
ImmunityBio, Inc.
Immatics US, Inc.
Vall d'Hebron Institute of Oncology
Acepodia Biotech, Inc.
Essen Biotech
National Institutes of Health Clinical Center (CC)
BioEclipse Therapeutics
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Fred Hutchinson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Eastern Cooperative Oncology Group
Fate Therapeutics
Shanghai Zhongshan Hospital
BGI, China
Incyte Corporation
Genocea Biosciences, Inc.
Instituto Oncológico Dr Rosell
ImmunoVaccine Technologies, Inc. (IMV Inc.)
PharmaMar
Fred Hutchinson Cancer Center
GlaxoSmithKline
MaxCyte, Inc.
National Institutes of Health Clinical Center (CC)